Back to Top Skip to main content

Surgeons perform first bioengineered blood vessel transplant in military patient

Development of the Human Acellular Vessel, or HAV, starts by taking living cells from a human blood vessel and placing them onto a tube-shaped frame. These vascular cells are kept alive in an organ chamber, growing around the tube-shaped lattice. Over time, the lattice that was used to seed the original vascular cells dissolves, and scientists remove the original cells so the new vessel doesn’t cause an immune response when it’s implanted. What is left is a solid, tubular structure made of human vascular material that looks and acts like a blood vessel -- thus, the bio-engineered and newly-grown blood vessel, or HAV. (USU medical illustration by Sofia Echelmeyer) Development of the Human Acellular Vessel, or HAV, starts by taking living cells from a human blood vessel and placing them onto a tube-shaped frame. These vascular cells are kept alive in an organ chamber, growing around the tube-shaped lattice. Over time, the lattice that was used to seed the original vascular cells dissolves, and scientists remove the original cells so the new vessel doesn’t cause an immune response when it’s implanted. What is left is a solid, tubular structure made of human vascular material that looks and acts like a blood vessel -- thus, the bio-engineered and newly-grown blood vessel, or HAV. (USU medical illustration by Sofia Echelmeyer)

Recommended Content:

Research and Innovation | Technology

An Army veteran in danger of losing his leg from vascular disease has become the first patient in the Military Health System to undergo transplantation of a new type of bioengineered blood vessel thanks to surgeons from the Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center.

Air Force Col. (Dr.) Todd Rasmussen, professor of Surgery and associate dean for Clinical Research at USU, performed the surgery at Walter Reed-Bethesda this month after getting approval for use of an investigational product called the Human Acellular Vessel, or HAV, developed by Humacyte, Inc.

“Military surgeons have been following and researching this technology for a number of years as potentially a new way to repair blood vessel injury on the battlefield. We are excited to see the product come to fruition, and for our team to gain real-world experience with it in the operating room at Walter Reed. Our ability to use this product to save this patient’s leg is a credit to a partnership that included the military’s medical research program, Humacyte, and a forward-leaning approach by the Food and Drug Administration.”

The rate of vascular injury during the wars in Iraq and Afghanistan was higher than that reported during previous wars, and faced with this challenge, the Department of Defense was in search of an off-the-shelf biologic conduit that could be used to save the limbs of service members. Repair of a damaged blood artery would normally involve surgically removing and using an extra vein that runs just under the surface of the length of the patient’s inner leg called the saphenous. However, some patients may not have an adequate sized vein, or they may have had the vein damaged during the original injury; a common situation in blast-injured service members. Using the patient’s own saphenous vein for repair also increases the time of an already complex operation, and requires another surgical incision that has its own risks.

The HAV was created by a team of clinician-scientists from Yale and Duke Universities led by Drs. Laura Niklason and Jeff Lawson, respectively, and has only recently been used in hundreds of civilian patients in the U.S. and around the world, mostly on a research basis. In 2011, amidst several deployments and while serving as the deputy commander of the U.S. Army Institute of Surgical Research, Rasmussen had an opportunity to see how the HAV worked and was able to study it himself in an animal model of vascular injury. For nearly a decade, Rasmussen has led collaborative efforts to help bring this innovative technique into the Military Health System. Because the HAV does not yet have full FDA clearance, Rasmussen worked with members of the FDA to get his own approval to use the investigational device at Walter Reed. Rasmussen believes this procedure could soon be the new way to help save limbs on the battlefield.

“I think this product could be a game changer for the management of vascular injury and vascular disease – it could eliminate the need for saphenous vein harvest or use of plastic vascular conduits. We’ve been enthused by its potential use on the battlefield, studied it in our military labs and supported its research in civilian centers, and it’s great to see it now diffuse into real-world practice,” Rasmussen said. “Injury to major blood vessels of the body is the most common cause of death and disability in combat and we need new technologies such as this to improve our ability to save lives and limbs. Because this product is made of neutral biologic material, it has the potential to be resistant to infection and become incorporated or adopted by the recipient patient. The fact that it can be bio-manufactured to a specific size and available for immediate, off-the-shelf use is also revolutionary.”

Development of the HAV starts by taking living cells from a human blood vessel and placing them onto a tube-shaped frame. Just as cells would normally grow inside a petri dish, these vascular cells are kept alive in an organ chamber and allowed grow around the tube-shaped lattice. As the cells are maintained in the chamber they secrete the strong structural substances that make up a blood vessel. During the process, the chamber generates a pulsating rhythm through the tube-shaped frame, mimicking a heartbeat and giving the new vessel the sensation of blood pressure as it is forming. Over the course of weeks, the cells and the strong framework they form begin to “think and behave” like a real blood vessel, Rasmussen said. Over time, the lattice that was used to seed the original vascular cells dissolves, and scientists remove the original cells so the new vessel doesn’t cause an immune response when it’s implanted. What is left is a solid, tubular structure made of human vascular material, which looks and performs like a blood vessel – thus, the bio-engineered and newly grown blood vessel, or HAV.

The HAV is then removed from the organ chamber, packaged in sterile preservative fluid, and stored ready for surgical implantation into a patient with an injured or blocked blood vessel. When sewn in place in the operating room, the HAV reroutes and restores blood flow around the vascular blockage or injury.

Since the finished framework that makes up the HAV is immune-neutral, Rasmussen noted, patients do not have problems “taking” the transplanted vessel, meaning the recipient’s body does not reject the HAV that it might otherwise not recognize because it’s a biologic originating from someone else’s vascular cells. Also, because the vascular framework can conform to any tube-shaped lattice, these vessels could potentially be made into various shapes and sizes to meet an individual patient’s needs, he said.

“Once the HAV is implanted, the patient’s own cells circulate through and hopefully make themselves at home to ‘redecorate’ the new vessel as their own” Rasmussen said. “Although further research needs to be performed to understand the long-term durability and features of this product, the hope is that as the HAV functions in the recipient patient, it will become that patient’s own ‘living’ vessel and last indefinitely.

“Having this innovative product reach the point of clinical use and study is a great example of the synergies that exist between university-based innovation, private industry, the DoD-medical research program and the FDA. It’s another example of how priorities and the lessons learned from war propel advances in medicine and the biomedical sciences – hopefully to the betterment of military and civilian patients.”

Disclaimer: Re-published content may have been edited for length and clarity. Read original post.         

You also may be interested in...

Call for abstracts open for Military Health System Research Symposium

Article
2/22/2021
Military personnel speaking in front of an audience at the Military Health Systems Research Symposium

Abstracts for this year’s MHSRS are due by March 31.

Recommended Content:

About the MHS | Research and Innovation

DHA IT helps beneficiaries, providers and workforce through pandemic

Article
2/12/2021
Several military personnel, wearing masks, filling out paperwork. One woman is giving the thumbs up sign

DHA IT Teams Deliver Innovative Solutions During Pandemic.

Recommended Content:

Technology | Coronavirus

WRNMMC’s participation in APOLLO program furthers cancer research

Article
2/4/2021
Two groups of vials on a table

The MCC serves as the preeminent cancer research and treatment facility within the Department of Defense.

Recommended Content:

Research and Innovation | Health Readiness

Innovative mobile technologies impact DOD health surveillance

Article
2/2/2021
Medical personnel using a syringe to inject a fluid into a test tube

Early detection of infectious diseases in the field to protect the troops.

Recommended Content:

Coronavirus | Research and Innovation | Technology

Solution Delivery Division

Fact Sheet
1/21/2021

The mission of Solution Delivery Division (SDD) is enhancing Health Service Delivery through exceptional Information and Technology.

Recommended Content:

Technology

NAMRU-SA partakes in virtual San Antonio postdoctoral research forum

Article
1/19/2021
Military officer sitting at her desk and smiling

For NAMRU-SA it was an opportunity to highlight the unit’s battlefield health and trauma care initiatives.

Recommended Content:

Research and Innovation

Joint Warfighter Medical Research Program

Congressional Testimony
1/11/2021

S. 3159, SAC Report for FY 2019 , 115-290 , Pg. 210

Recommended Content:

Research and Innovation

MHS operational innovations continue in battle against COVID-19

Article
1/5/2021
Two medical personnel, wearing full PPE, in an operating room

MHS innovations in 2020 include a new registry for real-time COVID-19 data and a system to free up hospital beds and protect patients from the disease.

Recommended Content:

Coronavirus | Research and Innovation | Innovation | Technology

DHA’s IT innovation continues during COVID-19 pandemic

Article
12/31/2020
Three military personnel, wearing masks, in front of a computer screen

IT innovations keep pace despite COVID-19 road blocks.

Recommended Content:

Coronavirus | Research and Innovation | Technology | MHS GENESIS

MTFs respond to COVID-19 with increased telehealth, drive-thrus

Article
12/29/2020
Military physician sitting at desk, talking to patient on his computer

COVID MTF innovations include more virtual health options and drive thrus.

Recommended Content:

Coronavirus | Technology

MHS Team Resiliency Awards recognize medical response to COVID-19

Article
12/22/2020
Sailors wearing masks, leaning on a table and writing on sheets of paper

Outstanding efforts recognized during Resiliency Awards

Recommended Content:

Coronavirus | Research and Innovation

Nurse-led research aims to improve battlefield medicine

Article
12/21/2020
Military nurses working on a simulated patient in a helicopter

[O]ne of their goals is to create novel solutions to optimize survival and functional recovery of burn casualties.

Recommended Content:

Combat Support | Research and Innovation

TRICARE Online Patient Portal

Fact Sheet
12/21/2020

TRICARE Online Patient Portal (TOL) is the Department of Defense (DoD) online patient portal providing eligible beneficiaries access to military hospital and clinic appointing, prescription (Rx) refill, DoD PP Health Record personal health data, Secure Messaging, Service Separation/Retirement and Nurse Advice Line.

Recommended Content:

Technology

USAMRIID scientist recognized by French for distinguished service

Article
12/4/2020
Two military officers on stage; one handing the other a certificate

Kugelman...identified genetic markers of persistence of the Chikungunya virus.

Recommended Content:

Health Readiness | Research and Innovation | Technology

METC improves surgical tech training with new laparoscopy standard

Article
12/1/2020
Surgical team in operating room

A laparoscopy is a low-risk, non-invasive surgical procedure used to examine organs inside the abdomen and repair or remove tissue.

Recommended Content:

Combat Support | Health Readiness | Research and Innovation | Technology
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 15

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.